Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's Disease

Core Insights - Vor Bio is hosting a live webcast to present late-breaking 48-week Phase 3 clinical data for telitacicept in primary Sjögren's disease, conducted in collaboration with RemeGen Co., Ltd [1][2] - The webcast will feature Vor Bio management and Dr. Ronald van Vollenhoven, who will discuss key efficacy and safety results from the trial [2] Webcast Details - The webcast is scheduled for Tuesday, October 28, 2025, at 4:30 PM Eastern Time [3] - A replay of the webcast will be available on the investor section of Vor Bio's website approximately two hours after the conclusion and will remain accessible for 30 days [3] Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, particularly through the development of telitacicept, a novel dual-target fusion protein [4] - The company aims to advance telitacicept through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions globally [4]